Henry E. Pelish, Chief Scientific Officer at Nuvalent, Inc. (NUVL), sold 4,538 shares at $80.54 ($362K) on 2025-01-06, disclosed to the SEC on 2025-01-08.
Scheduled sale ($362k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.28 | 712 | $56K | 15.4% |
| 2 | $78.28 | 712 | $56K | 15.4% |
| 3 | $79.33 | 428 | $34K | 9.4% |
| 4 | $80.54 | 1,343 | $108K | 29.9% |
| 5 | $80.54 | 1,343 | $108K | 29.9% |
| Total | $79.72 avg | 4,538 |
| $362K |
| 100% |
| Filing → |
| NUVL | SELL | 2026-03-16 | $3.4M | — | Filing → |
| NUVL | SELL | 2026-01-07 | $502K | — | Filing → |
| NUVL | SELL | 2025-10-17 | $2.6M | — | Filing → |